The news: The FDA sent aesthetics drugmaker Evolus an untitled letter about Instagram posts that overstate how fully and quickly the prescription injectable Jeuveau works.

The FDA notes the video in question is framed like an interview, featuring a young fashionable woman who says the line between her eyebrows is gone the day after treatment. The FDA also said the video frames the prescription injectable like an everyday cosmetic, oversimplifying its classification as a prescription drug and minimizing its risks.

Why it matters: The FDA is scrutinizing the overall presentation of social media promotion amid a broader enforcement ramp-up. The Evolus letter is the 29th FDA enforcement letter sent to pharma companies this year, more than four times the number issued from 2020 through mid-2025, per FDA data. For context, the FDA launched a crackdown on pharma direct-to-consumer ads in September 2025, and promised continued enforcement.

The issues cited in the Jeuveau video echo recent FDA TV enforcement. A Novo Wegovy ad received a letter challenging claims like “Live Lighter” as implying broader emotional benefits, while BeOne’s Brukinsa was cited for implying patients could maintain normal active lifestyles while downplaying side effects.

Social media is becoming a more visible part of the FDA crackdown. The Jeuveau letter is the second social media enforcement action this year, following a Pfizer Facebook ad letter in April, as the agency has also promised greater scrutiny of drug promotions on social platforms.

Implications for pharma marketers: The Jeuveau letter signals what may draw FDA scrutiny beyond individual claims. Informal elements that help content feel natural on social media—including conversational tone and lifestyle framing—can shape the overall message and warrant closer attention during early concept reviews.

The FDA’s concern about presenting Jeuveau like an everyday beauty product adds another consideration. Pharma marketers, especially in beauty and wellness, need to clearly distinguish between prescription drugs and cosmetics or other nonprescription products when they’re promoted alongside each other, even when that comparison is implied rather than explicitly stated.

This content is part of EMARKETER’s subscription Briefings, where we pair daily updates with data and analysis from forecasts and research reports. Our Briefings prepare you to start your day informed, to provide critical insights in an important meeting, and to understand the context of what’s happening in your industry. Not a subscriber? Click here to get a demo of our full platform and coverage.